NASDAQ, FOLD - Amicus Therapeutics
We are a clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of a new class of orally-administered, small
molecule drugs, known as pharmacological chaperones, for the treatment of a
range of human genetic diseases. Our lead products in development are Amigal
(migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for
Gaucher disease and AT2220 for Pompe disease. We completed our Phase 2 clinical
trials of Amigal, are currently conducting Phase 2 clinical trials of Plicera
and completed Phase 1 clinical trials of AT2220. Fabry, Gaucher and Pompe are
relatively rare disorders but represent substantial commercial markets due to
the severity of the symptoms and the chronic nature of the diseases. The
worldwide net product sales for the five currently approved therapeutics to
treat Fabry, Gaucher and Pompe disease were approximately $1. ...
Read SEC Filing on NASDAQ.com »